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ABSTRACT

Intra-abdominal

hypertension

(IAH)

and

abdominal

compartment

syndrome (ACS) are increasingly recognized in critically ill patients; no nonoperative treatments exist, and mortality remains high.
The purpose of this thesis was to prospectively characterize the incidence
of IAH in a mixed medical-surgical intensive care unit, and to test the potential
therapeutic benefit of carbon monoxide (CO) and hydrogen sulphide (H2S) using
an animal model of ACS. IAH was diagnosed in 30% of patients on admission;
further 15% developed IAH during ICU stay. Incidence of ACS was 3%, with
obesity, sepsis, mechanical ventilation and 24-hour fluid balance as independent
predictors, also predicting ICU mortality. In a rat model of ACS, CO and H2S
were found to improve ACS-induced microcirculatory dysfunction, inflammation,
cell death and overall organ dysfunction.
IAH incidence in the critically ill is high, with its correction possibly
reducing mortality. CO and H2S show promise in animal model of ACS, as
potential therapeutics.

Keywords:

intra-abdominal hypertension, abdominal compartment syndrome,
carbon monoxide, hydrogen sulphide, CORM-3, GYY4137, hepatic
microcirculation
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CHAPTER 1

INTRODUCTION AND HISTORICAL REVIEW
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CHAPTER 1: INTRODUCTION AND HISTORICAL REVIEW

1.1

INTRA-ABDOMINAL

HYPERTENSION

AND

ABDOMINAL

COMPARTMENT SYNDROME
Intra-abdominal

hypertension

(IAH)

and

abdominal

compartment

syndrome (ACS) are increasingly recognized clinical entities in the critically ill
patient. IAH is likely more common than previously established and it is unknown
whether IAH is a sign of illness severity or rather a disease that, when treated,
will improve patient outcomes.

1.1.1 Overview and History
The history of IAH and ACS is one typical of many topics in medicine. An
ebb and flow of use, development, and perception, falling in and out of favour
with eventual permanence in practise or a complete fall from favour as the final
value of a measurement, technique or therapeutic is decided upon (Figure 1.1)
(1).
The first description of the effects of IAP dates back to at least the mid- to
late 1800s. Commenting on respiration, Marey described the inverse relationship
between thoracic excursion and abdominal movement, although no actual
measurements were made (2). Dr. Matthews Duncan, an obstetrician, described
the influence of the abdominal cavity and “the retentive power of the abdomen,”
acknowledging the abdomen as a compartment that when violated loses
influence over abdominal organs (3). In Germany, Braune successfully measured
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Figure 1.1. Historical timeline of IAH/ACS diagnosis.

4
IAP via the rectum, by inserting a glass tube connected to a graduated cylinder.
After injecting water into the rectum, he measured the column of water at 40cm,
and found minimal variation between individuals regardless of the amount of
water injected. However, the amount of pressure was increased when
participants performed a Valsalva manoeuvre, and was reduced by supine
positioning (4). Rapid recognition of the IAP and advancement of measurement
techniques and improved understanding of the effects of altered IAP on normal
physiology followed. Before the turn of the 19th century, the IAP could be
measured via the bladder (5); it was recognized that high pressures resulted in
reduced urine output and decreased venous return. In animals, pressures of 2746cm H2O were found to be fatal, due to impaired respiration, decreased cardiac
distension and low blood pressure (6). In 1911, Haven Emerson (7) re-affirmed
Marey’s original observations: using a canine model, Emerson demonstrated that
contraction of the diaphragm resulted in an elevation of IAP, and that
anaesthesia and neuromuscular blockade decreased IAP. Furthermore, he
demonstrated a cardiac aetiology (rather than respiratory a one) in the setting of
significant IAP which ultimately led to death (7).
For the following 40 years, IAP and IAH were not well studied. An
anaesthetist, Dr. Baggot (8), attributed elevated IAP to the high mortality
following emergency surgery for wound dehiscence. Based on his observations,
he hypothesized that it was the closure under tension, rather than the
dehiscence, that led to increased IAP and, ultimately, death. Additionally, he
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suggested leaving the abdomen open; a technique developed by Ogilvie during
World War II (8,9).
Through the 1960s and 70s, much of the work related to IAP and IAH was
related to ascites and laparoscopy (10–14). It was during this time that nonsurgical management of elevated IAP, through paracentesis, was demonstrated
(11). While the term ‘abdominal compartment syndrome’ was not formally used to
describe a clinically evident elevation in IAP until 1989, already in 1984 Kron et al
(15) described the “landmark” clinical and animal study around what is now
called ACS. The authors described four patients undergoing abdominal aortic
aneurysmal repair who progressed to medically refractory anuria (15). Upon
decompression, an immediate output of urine was noted, even without
identification of any intra-abdominal pathology. The single patient who did not
undergo decompression died, while the other three survived to discharge. Early
experiments on canines by the same authors suggested that an IAP of 20mmHg
reduced renal function. This process was unresponsive to cardiac output
augmentation (16,17). Kron et al (15) measured IAP as high as 40 and 77 mmHg
in 10 post-operative patients. Four of the seven anuric patients with IAP >
25mmHg received decompression and diuresied immediately. The conclusions of
the study form the underpinning of ACS.
Interestingly, around the same time, Smith et al (18) reported the case of a
woman who received a decompressive laparotomy for anuria post duodenal ulcer
repair and diuresed immediately following decompression. The authors go
insofar as to compare the decompression to limb compartment syndrome and
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fasciotomy. The authors did not believe that IAP measurements, if available,
would have been helpful. Instead the diagnosis was made on the basis of
relatively normal hemodynamics and anuria (18).
At the end of the 1980s, IAP measurements continued to be described in
the intensive care unit population. At the time, measurements were done using
the bladder exclusively, using higher instillation volumes and the pubic
symphysis as a zero reference point, resulting in pressures much higher than
those seen today (19). Fietsam et al (20) coined the term ‘abdominal
compartment syndrome’, after describing bedside laparotomy for decompression
due to ruptured AAA repair in four patients. All of the patients had received >25L
of blood and fluid, and a Marlex mesh had been placed at the time of
decompression. In the mid-1990s, two reviews were published on IAH/ACS,
followed by an ever-growing body of literature describing the causes, risk factors
and pathophysiology of IAH/ACS (21,22). IAH and ACS have expanded beyond
the post-operative patient population to include virtually all critically ill medical,
trauma and surgical patients.

1.1.1.1

Modern History – The World Congress

The key developments in the 2000s arose largely due to increasing
recognition of IAH/ACS as a common, yet under-recognized, phenomenon and
physiologic sequelae of the pneumoperitoneum of laparoscopy. Further,
“damage control” surgery, as well as the concept of the open abdomen and
abdominal decompression became more popular. The creation of the World
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Society of the Abdominal Compartment Syndrome (WSACS) in 2004 improved
recognition of IAH/ACS by intensivists. The WSACS is an organization headed
by a group of international physicians and surgeons, with a mandate to promote
IAH/ACS research and education. The society accomplishes these goals by
hosting an international clinical congress every 2-3 years. The Society also
produces evidence-based algorithms defining patient populations that benefit
most from regular IAP measurements, thereby providing a standardized
approach to prevention and treatment.
The first consensus guidelines from the WSACS were released in 2006
(23), followed by a 2013 update (24). Additionally, clinical practice guidelines and
recommendations for research were released in 2007 (25) and 2009 (26),
respectively . Perhaps the most important results were the guidelines that
recommend a common technique for IAP measurement. The expert panel
established the modified Kron technique as the preferred method for measuring
IAP. Prior studies may have had falsely elevated IAP measurements due to a
higher instillation volume (50ml versus the current practice of 25ml), and a zeropoint reference of the symphysis pubis rather than the mid-axillary line.
The consensus guidelines suggested screening for IAH/ACS in an
intensive care unit population if risk factors were present on admission. Any
patient admitted to the intensive care unit with two or more of the risk factors
listed in Table 1.1 should have a baseline IAP measurement. However, upon
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Table 1.1.

Risk factors for the development of IAH.
Adapted from Holodinsky et al (27) and WCACS consensus
guidelines (24).

Category

Risk Factor

Odds Ratio

Demographics

Obesity
Age (per year)

5.1
2.8

Diagnosis

Sepsis
Intra-abdominal infection
Abdominal surgery
Pancreatitis
Liver failure
Gastro-intestinal bleed
Ileus
Respiratory failure
ARDS

2.4
2.5
1.9
4.7
2.1
3.4
2.1
1.9
3.6

Disease Severity

APACHE II Score (per point)
Base deficit
Acidosis
Shock
Hypotension
Massive resuscitation
Positive fluid balance (per litre increase)

1.7
1.2
1.9
4.7
2.1
2.2
5.2

Other

Mechanical ventilation
PEEP >10cm H2O

6.7
2.4
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examination of the risk factors present, virtually every intensive care unit patient
meets at least two criteria. Additionally, the criteria themselves are poorly
defined. The lack of high-quality and rigorous literature on which to generate
evidence-based guidelines for the measurement and management of IAH/ACS is
one of the recognized drawbacks. This is further highlighted by recent metaanalysis and systematic reviews (27–29) attempting to characterize the
prevalence and risk factors for IAH/ACS: significant heterogeneity exists, with
respect to definitions of IAH, measurement techniques and patient populations
studied.

1.1.2 Definition of IAH
IAH is the sustained or repeated pathological elevation of intra-abdominal
pressure (IAP) to ≥12mmHg, as defined by the WSACS consensus guidelines
(24,25). An acknowledged limit of this definition is establishing the definition of
“sustained”. A single measurement over 12mmHg may not be clinically relevant if
all other measurements are less than 12mmHg. Similarly, it is unknown whether
maximal, mean or median IAP should be used to determine the presence or
absence of IAH. Total time spent above a certain IAP may have the most
significance clinically, but continuous IAP measurements have not been well
studied, or likely to be practical. This has led to significant heterogeneity in the
published literature: many definitions of IAH are used and this is compounded
with evolving IAP measurement techniques. This is particularly evident prior to
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consensus guidelines in 2006 (when the new instillation volume and reference
point were adopted).

1.1.3 Epidemiology of IAH
The incidence and prevalence of IAH are challenging to determine, for a
number of reasons. First, IAH is an acute and usually transient disease,
applicable to a very specific population of patients who are critically ill. Second,
the incidence (the number of new cases of IAH during the time period of the
study) is not to be confused with incidence rate (the number of new cases of IAH
in person-years). Incidence assumes each patient is at risk for the same period
of time.
Prevalence is typically used to describe point prevalence. For example,
the point prevalence would be the number of patients who had IAH at a specific
date and time of the year, not to be confused with period prevalence (the number
of patients who had IAH at any time during the study period). Prevalence is the
sum of the point prevalence at the beginning of the interval, plus the incidence
over the time interval. Thus, the best measure is the number of new cases of
IAH, with the assumption that no patients had IAH at the beginning of the study
period. This measure is equivalent to incidence or period prevalence.
Finally, the definition of IAH used can greatly impact the reported
incidence. Videl et al (30) adhered to reporting guidelines established by the
WSACS and found 31% of patients had an IAP ≥12mmHg on admission, 54%
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had IAPmean ≥12mmHg over the study period and 61% had IAPmax ≥12mmHg
over the study period.
The incidence of IAH has been described in a wide subset of discrete
patient populations, with ranges from 20 to 80% depending on the study
population in question, and technique for measuring IAP (31–33). When
considering only studies in consecutive mixed-medical intensive care unit
patients using the modified Kron technique, the incidence of IAH ranges from 30
to 61% (Table 1.2).
Although most studies do not include a measurement of error, standard
error can be calculated. Combining the results of the four published studies using
appropriate methods (34), the incidence of IAH is 40% (95% CI: 33%-47%). This
is much higher than that cited in a more recent literature, in populations deemed
high-risk (31). In a retrospective study Blaser et al (31) demonstrated that
increased screening for IAH was not associated with increased detection of IAH
(20%). The largest prospective study in a mixed medical-surgical ICU to-date is
out of Australia. Iyer et al (35) included 403 consecutive admissions, with a
reported incidence of 39%; IAH was defined as two consecutive readings of
≥12mmHg. The results however may lack generalizability since the majority of
admissions were cardiothoracic surgery patients and overall mortality was 11%.
Risk factors for the development of IAH have largely been established
based on retrospective studies, a lack of clear definitions, or the use of
heterogeneous measurement techniques (27). Additionally, both the size and
characteristics of the populations have been variable. The majority of studies
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Table 1.2.

Study

Prevalence of IAH in modern mixed ICU populations.

Population

Type

Size

IAH Definition

Incidence
(±2 SE)

Iyer et
al
(2014)

Mixed
Prospective
Medical/Surgical

403

IAP≥12mmHg in
2 consecutive
measurements

39±5%

Kim et
al
(2012)

Mixed
Prospective
Medical/Surgical

100

IAPmax≥12mmHg

42±10%

Dalfino
et al
(2008)

Mixed
Prospective
Medical/Surgical

123

IAP≥12mmHg in
2 consecutive
measurements

30±8%

Videl et
al
(2008)

Mixed
Prospective
Medical/Surgical

83

IAPmax≥12mmHg
IAPmean≥12mmHg
IAPmax≥12mmHg
(Admission)

64±10%
54±10%
31±10%

709

−

40±7%†

Total

IAP, intra-abdominal pressure; SE, standard error
†

Calculated using random-effects modeling (I2=71%); SE = √

reported but calculated for this table

𝑝 ×(1−𝑝)
𝑛

: not
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report on a specific patient population, such as trauma, mechanically ventilated
patients, and those deemed high risk of developing IAH (27,28,31). Few studies
include a sample size or power calculations.
Whether or not IAH is an independent risk factor for mortality is
controversial. Some literature supports the notion of IAH as an independent
predictor (30,36–38), while some studies show no association (35,39,40). In a
meta-analysis of individual patient data from 1669 patients, Malbrain et al (28)
found an IAH incidence of 27%, using the mean of daily IAP and a cutoff of
12mmHg. Furthermore, the results suggest that IAH was an independent
predictor of mortality, in addition to elevated sequential organ failure assessment
(SOFA) score, simplified acute physiology score (SAPS) II score, and a surgical
admission.
The current body of evidence suggests IAH is common in critically ill
patients, particularly trauma, as well as post-operative patients. Other than data
from a single modern study, the incidence of IAH in a mixed-medical ICU is not
known. Further, methodologically rigorous study is required to establish both the
true incidence of IAH, and clinically important and measurable risk factors for the
development of IAH.

1.1.4 Risk Factors for the Development of IAH
The risk factors for the development of IAH have been reviewed
systematically and are numerous (Table 1.1) (27). The WSACS describes a
lengthy list of risk factors, broadly categorized as those relating to diminished

14
abdominal wall compliance, increased intra-luminal contents, increased intraabdominal contents, capillary leak/fluid resuscitation and others (24). Many of
these are limited, however, by the amount and quality of evidence available. The
majority of risk factors come from studies of a single small study with less than
150 patients (30,41). The definitions of the described risk factors also vary
substantially.
The larger studies investigating risk factors have been performed in
specific patients cohorts such as trauma patients, patient with pancreatitis, or
only those who were mechanically ventilated (24,27). This limits external validity
of the data (42). When considering consecutive mixed medical-surgical ICU
patients, the best predictors for the development of IAH have been established
by Iyer et al (35). Multivariable regression analysis showed that elevated lactate,
high SOFA score, massive fluid resuscitation, obesity, hemoperitoneum and
abdominal distension were all predictive of developing IAH on multivariate
regression. The finding of abdominal distension as a predictor is relevant, given
that physical exam is often quoted as unreliable as a predictor of IAH (43,44).
While the WCACS recommends measuring IAP in patients with at least two risk
factors, Iyer et al found this to be only 45% specific. In patients with three or
more risk factors, sensitivity was 75% and specificity was 76%. If applied to every
ICU admission, almost all patients would meet criteria for the routine
measurement of IAP; however it is clearly not important in all patients (31).
Risk factors for the development of ACS have been poorly studied outside
of the trauma population (27,45,46). The commonly cited risk factors include
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severe organ derangements including oliguria, massive blood transfusion,
hypothermia and elevated APACHE II score (27).
Given the number of risk factors for the development of IAH, some
physicians advocate surveillance in nearly all patients in an ICU (47). While the
2013 consensus guidelines suggest patients with two or more risk factors in the
intensive care unit undergo surveillance for IAH with regular IAP monitoring every
4 hours, the frequency of measurement is not evidence-based (24). The
recommendation is made, in part, due to the inexpensive nature of IAP
monitoring and the limited harm to the patient. Although there is a theoretical risk
of higher urinary tract infections, this has not been shown even in large cohorts
(48). It still remains to be established, however, whether increased surveillance
leads to a decrease in mortality (31,42,47).

1.1.5 Clinical Features and Diagnosis
The clinical features of IAH are subtle and this has led to the
recommendation of surveillance for patients deemed at high risk of developing
IAH (24). Indeed, given the breadth of patient cohorts in which IAH/ACS has
been described, including both surgical and non-surgical, it is understandable
why high suspicion is required to accurately detect IAH. The IAP that causes
end-organ dysfunction depends on the individual patient, abdominal wall
compliance and disease process (49). Similar to cerebral perfusion pressure, the
abdominal perfusion pressure [Mean Arterial Pressure (MAP) – IAP] has been
suggested as a method to assess the adequacy of blood flow and the severity of
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IAP and may be a relevant end-point for resuscitation (50). An IAP of 15mmHg
has been shown to have negative influence on perfusion and organ dysfunction,
and reflects laparoscopy settings during surgery (51). Table 1.3 outlines the
grading scheme of IAP, where normal is defined at less than 12mmHg. In a noncritically ill patients, normal values are as high as 7 mmHg (49).
The current practices of most ICUs are quite variable (31,52). Compared
to IAP measurements, the clinical exam has unreliable sensitivity and specificity
(43,44), and, therefore, unless clinicians are aware of IAH/ACS as a common
entity in critically ill patients, it may be missed.
The modified Kron technique is the most accepted method of measuring
IAP, and is recommended by the consensus guidelines (24). The technique uses
an existing indwelling urinary catheter to transduce the pressure of the bladder,
which accurately measures IAP. The measurement is very reproducible and
requires minimal training to perform. Briefly, the urinary catheter is completely
drained, and then cross-clamped. A pressure transducer is attached proximally
and placed at the mid-axillary line with the patient supine. Twenty-five millilitres of
sterile normal saline is then injected. The IAP measurement is taken at endexpiration to ensure relaxation of the abdominal wall; no routine paralysis is
required (53).
When diagnosing elevated IAP, it is important to reflect on factors other
than relevant pathology that may cause abnormal elevation. Pain, agitation and
accessory muscle breathing may increase thoraco-abdominal tone and produce
high, non-pathologic elevated IAP measurements. Neuromuscular blockade is, in
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Table 1.3.

Grades of intra-abdominal hypertension.

Grade

IAP (mmHg)

I

12-15

II

16-20

III

21-25

IV

>25
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fact, a recommended treatment for elevated IAP (54). Body positioning, including
elevation of the head of the bed above 20 degrees, can increase IAP. This is an
important consideration in patients exhibiting elevated IAP, who are being treated
for head injuries or severe lung disease.
Questions still remain with regards to exactly which patients would benefit
from routine surveillance for IAH with regular IAP. In addition, the frequency of
measurements still remains to be agreed upon (31,47).

1.2

PAHTOPHYSIOLOGY OF IAH
The abdomen is a closed compartment, contained by fixed and flexible

boundaries. The spine, pelvis and costal margin are relatively inflexible, while the
abdominal wall and diaphragm are comparatively elastic.

1.2.1 Intra-Abdominal Pressure
Given the primarily fluid nature of abdominal contents (49), the abdominal
compartment generally conforms to Pascal’s established principles. The pressure
exerted on the abdominal boundaries will be directly related to the intraabdominal volume (IAV) and the compliance of the abdominal wall. Similar to
other compartments, the pressure increases exponentially at a critical volume
(55). Further, the pressures, but not the curve shape, are influenced by
abdominal wall compliance, with low abdominal wall compliance leading to higher
pressures at the same volume (56).
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While the abdominal wall is the most compliant boundary, the diaphragm
does have elasticity and is dynamic. During the respiratory cycle, the diaphragm
relaxes and contracts, generating IAP variability. The nadir of pressure during
this cycle is at end-expiration, making it important to consider when IAP is
measured (55).
Much of the research surrounding the effects of elevated IAP on human
pathophysiology has been gained from studies of laparoscopy (51,57,58), or
hypothesized from more controlled and rigorous animal studies (59–62).
Laparoscopic abdominal surgery requires a pneumoperitonium. In adults, the
pneumoperitoneum is established with CO2 gas at a pressure of 15mmHg. At this
value, there is an increase in systemic vascular resistance (SVR) and a decrease
in cardiac output proportional to the IAP (51). The mean arterial pressure is
increased as the SVR increase overcomes the decrease in cardiac output.
Pneumoperitoneum is generally well tolerated in healthy patients, and the rise in
IAP occurs only for the duration of surgery. This is significantly different from
elevated IAP in a critically ill patient with other physiologic derangements,
particularly hypovolemia and elevated intrathoracic pressures from positive
pressure ventilation (58,63,64). The effects of elevated IAP on different organ
systems are outlined in Table 1.4, and are further discussed in Appendix II.
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Table 1.4.

Organ effects of elevated IAP.

System

Cardiac

Effects

Decreased ventricular end-diastolic volume
Increased afterload
Reduced preload through compression of IVC, SVC and
portal vein
Reduced CO

Respiratory

Impaired diaphragmatic function
Reduced pulmonary compliance
Pulmonary vasoconstriction
Increased intra-thoracic pressure

Gastrointestinal

Splanchnic hypoperfusion
Bacterial translocation
Bowel ischemia

Liver

Reduced arterial and venous flow
Cellular dysfunction

Renal

Reduced arterial flow
Reduced glomerular filtration
Oliguria

Neurologic

Elevated intra-cranial pressure
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1.2.2 Ischemia-Reperfusion (I/R) and Inflammatory Injury in IAH/ACS
Elevation of IAP reduces blood flow to abdominal organs, producing tissue
hypoxia (51). The reduced oxygenation leads to an increase of intracellular
calcium, which is responsible for upregulation of many downstream pathways,
including those related to cellular necrosis (65). Necrotic cells release their
contents; once they enter systemic circulation, activation of the transcription
factors responsible for the upregulation of pro-inflammatory cytokines and
chemokines
characterised

results
by

(66).

rolling,

This

triggers

leukocyte

eventually progressing

to

activation
firm

cascade,

adhesion

and

extravasation from the circulation into the affected tissue (67). Each step is
mediated by the differential expression of adhesion molecules, both on the
leukocyte and endothelium. As a result, the endothelial barrier becomes leaky,
leading to the formation of edema, which itself contributes to further tissue
damage. In parallel, hypoxia also triggers activation of apoptotic pathways (a
process mediated by various caspases), further contributing to an increase in
overall cell death.
While the initial ischemic insult leads to deleterious cellular effects, the
sudden reperfusion of tissue also carries harm at the cellular level, via the
production of reactive oxygen species (ROS). The lipids in cellular membranes
are vulnerable to peroxidation by these highly-reactive entities, leading to
microvascular changes, which can precede macroscopic organ damage (68).
Morris et al had suggested that the reperfusion injury following abdominal
decompression is a significant contributor to mortality in ACS patients (69).
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ROS are free radicals that trigger leukocyte recruitment, and can lead to
tissue

injury

through

neutrophil

activation

(70).

Neutrophils

are

polymorphonuclear granulocytes, containing various proteolytic and ROSproducing

enzymes

(myeloperoxidase

(MPO),

elastase,

proteases,

peroxynitrites). Activated neutrophils release the granules during oxidative burst,
which can further compound ischemia-induced tissue damage. Different organ
systems have varying susceptibilities to I/R injury; for example, the small bowel
seems to be more susceptible to I/R than the large bowel (71).
The induction and deflation of pneumoperitoneum appears to represent an
I/R injury model in humans. It has been demonstrated that post-operative
laparoscopic cholecystectomy patients have elevated liver enzymes. Additionally,
there is evidence of ROS-induced lipid peroxidation after deflation of the
pneumoperitoneum (72). In a systematic review of the oxidative stress, as it
pertains to pneumoperitoneum, there was agreement that pneumoperitoneum
decreased splanchnic blood flow in a pressure- and time-dependent manner
(73). It is unlikely, however, that this effect is entirely due to the
pneumoperitoneum, since open operations also induce oxidative stress. Further,
the pneumoperitoneum associated with surgery is considerably different from
that of the pathologic rise in IAP leading to IAH/ACS; these are less controlled,
and in generally unwell patients, coupled with many pathophysiologic
derangements (such as hypotension and mechanical ventilation) (58,63,64).
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1.2.3 From IAH to ACS
The aforementioned pathophysiology is evident and exacerbated in
abdominal compartment syndrome. The first typical clinical sign is oliguria in an
adequately resuscitated patient, progressing to additional intra-abdominal and
systemic effects (15). As a result, the patient will become more unstable, and if
untreated, will die. The incidence of ACS is quite variable depending on the
patient cohort: in a mixed medical and surgical population, ACS affects at least 23% of patients and has a mortality of approximately 80%, even with surgical
decompression (23). Beyond prevention, the only current treatment option
available is decompressive laparotomy to release the abdominal pressure and
allow organ perfusion, often performed at the bedside. Urine output will increase
almost immediately after decompression (74). Unfortunately, the ensuing I/R
injury is significant, and may be responsible for the observed high mortality rate
(69).
Intra-abdominal organs, including the liver, kidney and bowel, will have
experienced a significant reduction in the blood flow for a period of time. The
sudden increase to nearly normal flow may result in significant organ dysfunction
(5,62,75–77). This pattern has been observed in several other models of
compartment syndrome (CS), particularly that in the extremities. In acute limb
CS, fasciotomy to release the compartment pressure often results in a severe
reperfusion injury (78) which can be more substantial than the ischemic insult
(69).
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While it is likely that a patient cohort may be at particularly high risk of
progression to ACS, the incidence is relatively lower than that of IAH, and thus
has been less studied (27). In the absence of treatment, not all patients who
develop IAH progress to ACS; it remains a challenge to determine who is at the
highest risk and who should undergo regular surveillance, since this is the most
reliable approach to early detection of ACS. Some researchers advocate for early
abdominal decompression, as the management of the open abdomen has
progressed significantly in recent years (79).

1.3 THERAPEUTIC APPROACHES TO IAH AND ACS
As previously mentioned, there is disagreement in the literature on
whether IAH is an independent predictor of mortality (30,35–40). The 2013
consensus guidelines recommend efforts or protocols to avoid sustained IAH,
compared to inattention to IAP (24). Non-operative management strategies are
both preventative and therapeutic. While a number of measures have been
suggested, there have been no studies comparing treatments or demonstrating a
reduction in mortality, with all recommendations based on low-grade evidence
(24). Preventative measures include increased awareness, surveillance of those
at risk, and using protocols for management of IAH/ACS. Cheatham et al
prospectively studied nearly 500 patients with an open abdomen, managed with
a protocoled approach based on the 2006 consensus guidelines (23). This
resulted in an increase in, adjusted, survival to discharge compared to a
historical control (79).
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Other treatment options are outlined in Table 1.5, with the goal of any
treatment for IAH/ACS being a reduction of the IAP, in order to restore optimal
perfusion to organs. Given the nature of critically ill patients, this may represent a
challenging goal, particularly with respect to fluid management and the
appropriate response to the pathology accountable for the patient’s condition
(80).

1.3.1 Surgical Decompression
If end-organ failure occurs in the setting of elevated IAP, prompt surgical
decompression is warranted (24). While the procedure has the effect of restoring
organ blood flow, it is not without significant morbidity. Further, mortality remains
high even with decompression. Definite abdominal closure can be challenging,
and is associated with significant long-term complications (80).

1.3.2 Pharmacological Approaches
Although no study has compared potential therapeutics for IAH/ACS in
humans, a number of pharmacological therapies have been tested in animal
models of IAH/ACS. Some have shown to be effective, including doxycycline
(81), minocycline (82), dopamine (76) and octreotide (83). In animal models of
limb CS and I/R, gas-releasing molecules have shown therapeutic potential, by
reducing the levels of tissue injury and microvascular dysfunction associated with
these conditions (84,85).
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Table 1.5.

Treatment of IAH/ACS.

Intra-Luminal
Contents

Space Occupying
Lesions

Abdominal Wall
Compliance

Naso/orogastric tube
and/or rectal
tube

Ultrasound or CT to
identify lesions

Adequate sedation
and pain control

Goal directed
resuscitation

Prokinetic
agents

Percutaneous
drainage

Remove constrictive
dressings

Hemodynamic
monitoring

Limit enteral
nutrition
enemas

Surgical evacuation
of lesions

Reverse
Trendelenberg
neuromuscular
blockade

Consider
hemodialysis

Colonoscopic
decompression

Fluid/Organ
Perfusion
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1.3.3 Gasotransmitters and Gas Releasing Molecules
Gaseous signalling molecules, or gasotransmitters, are a relatively new family of
molecules. The term gasotransmitter was first introduced by Wang in 2002, to
describe the cellular actions of nitrous oxide (NO) and carbon monoxide (CO)
(86). Wang further suggested the candidacy of hydrogen sulphide as a
gasotransmitter, which has since been confirmed (86,87). The concept of gases
as signalling molecules was demonstrated in the 1980s in vascular endothelium
(88), with the discovery that endothelium-derived relaxing factor was nitric oxide,
resulting in a Nobel Prize (89). At the same time, NO was shown to have
analgesic effect similar to morphine (90), and acted as an agonist for membrane
opioid receptor (91,92).
Gasotransmitters differ significantly in size, compared to normal cell
signalling molecules, and easily diffuse through the cell membranes. There are
many

distinct

differences

between

classic

neurotransmitters

and

gasotransmitters: the latter are released in the cytoplasm rather than via an
exocytosic vessel, there is no re-uptake mechanism or enzymatic removal –
rather

concentrations

decrease

via

oxidation,

radical

scavenging

and

methylation; in addition, membrane receptors are not required for action. Criteria
required to meet the definition of a gasotransmitter are outlined in Table 1.6.
The three best-described gasotransmitters are nitric oxide (NO), carbon
monoxide (CO) and hydrogen sulphide (H2S), all of which are endogenously
produced. They have been shown to function as vasodilators, anti-inflammatory
and cytoprotective agents at physiologic concentrations (Table 1.7) (87,93–95).
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While the mechanisms of action of each continue to evolve and are in some
ways unique, there is significant overlap and even inter-play among one another
(96). A number of current therapeutics act through mechanisms that rely on
gasotransmitters (97). Perhaps the most well-known and commonly used
clinically are nitroglycerin and the phosphodiesterase-5 inhibitors. All of the
gasotransmitters are present at basal concentrations in many cells, and have
been shown to increase or decrease in various disease states. A significant body
of literature exists around the idea of gasotransmitters as potential therapeutics;
various novel releasing molecules have been synthesised, and significant results
have been demonstrated in a number of animal models of disease (87,94,98).

1.3.3.1

Carbon Monoxide

CO is a highly publicized toxic molecule, as a cause of sudden death at
home from leaky furnaces and as a toxin in cigarettes; general avoidance of CO
is mandated to remain healthy, and alive. As a colourless, odourless, tasteless
and initially non-irritating gas, CO monitors are recommended for households,
while warnings are placed on cigarette packages. The mechanism of acute
toxicity, and eventual death if untreated, is the formation of a fairly stable
complex, carboxyhemoglobin (COHb). COHb interferes with the normal oxygencarrying capacity of hemoglobin, resulting in hypoxia. Concentrations of 100ppm
have been shown to ellicit neurologic symptoms; concentrations of 1600ppm
cause death within 2 hours. The 20% level of COHb in humans will elicit
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Table 1.6.

Criteria for gasotransmitters.

1) Small gaseous molecules
2) Membrane permeable and do not rely on cell repectors or exocytosis
for cell-signalling
3) Endogenously generated in a controlled manner
4) Specific function at physiologic concentration that is mimicked with
exogenous administration
5) Specific cellular and molecular targets which many or may not be
mediated by second messengers
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Table 1.7.

Characteristics

of gasotransmitters

nitric

oxide,

carbon

monoxide and hydrogen sulphide.
Nitric Oxide

Carbon Monoxide

Hydrogen Sulphide

Molar Mass
(g/mol)
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Substrate

L-arginine

Heme

L-cysteine

Endogenous
Production

NOS

HO

CBS, CSE

Breakdown
Products

Nitrite/Nitrate

None

Thiosulphate,
Sulphate, Sulphite

Identified
Targets

sGC, KCa,
Heme Proteins
Cytochrome C
Oxidase

sGC, KCa,
Heme Proteins
Cytochrome C
Oxidase

Ca, KATP,
Heme Proteins,
Cytochrome C
Oxidase, PDE

Singalling
Pathways

cGMP, p38 MAPK,
ERK, PI3K/PKB

cGMP, p38 MAPK,
ERK, PI3K/PKB

cGMP, p38 MAPK,
ERK, PI3K/PKB

NOS, Ras

PERK, p21

JNK

Free Radical

Yes

No

No

Direct
Oxidant
Scavenger

No

No

Yes

Donors

Organic Nitrates
Sodium Nitroprusside

CO-RMs

Sodium Salts
Synthetic Donors
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symptoms, and death will occur at 50-80% saturation. Smokers have been
demonstrated to have slightly elevated levels of 10-15% COHb, as opposed to
non-smokers whose basal levels of COHb are 1-3% (99). The exact cellular
mechanism of death due to CO overdose is still debated, but is most likely due to
COHb-associated hypoxia, with minor extra-hemoglobin influence (100).
Despite its toxicity, nearly every organism contains CO, the output of
which has been demonstrated to increase during the stress response (101).
Under homeostatic conditions, CO is produced as a metabolite of heme
degradation pathway. Heme is a vital cofactor and regulator of oxygen transport
protein (hemoglobin), respiration and inflammation (102). In the liver, the quantity
of heme is comparatively high, as it provides the catalytic domain for monooxygenase enzymes, such as cytochrome P-450(103). Heme is also a functional
moiety in a number of signal transduction proteins, including NO synthases
(NOS) and guanylate cyclase (GC), with generate cGMP (104,105).
Heme oxygenase (HO), the enzyme responsible for heme catabolism, has
been identified in nearly every species ever studied. Heme is broken down by
HO into biliverdin (which immediately gets converted to bilirubin) and CO gas, a
reaction facilitated by NADPH (ref). Three genetically distinct forms of HO have
been characterized: the inducible heme oxygenase-1 (HO-1), and the
constitutively expressed heme oxygenase-2 (HO-2) and heme oxygenase-3 (HO3). HO-1 has recently been identified as the 32kDa heat-shock protein (HSP32)
that can be induced by a number of stimuli (106), particularly oxidative stress,
thus suggesting a protective role (103).
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Originally described as a metabolic enzyme to aid in turnover of heme
proteins, HO-1 has more recently been identified as paramount for a number of
agents to impart effect: statins, acetaminophen and prostaglandins (107).
Induction of HO-1 prior to a stress results in significant cell and tissue protection.
While the mechanism of effect has not been clearly elucidated, increasing
evidence suggests the generation of endogenous CO is responsible for the cell
and tissue protection.
Thus, the physiological role of CO is clearly beyond that of a waste
product. The mechanisms of action for CO are largely mediated through metalbinding, particularly with heme-containing proteins: soluble GC, cytochrome c
oxidase and cytochrome P450 (98). Further, a clear interaction with NO has been
described, via the effect on inducible NOS (iNOS) (98). The rapid upregulation of
iNOS by CO is complemented by an increase in HO-1, which leads to more CO
(108,109), as well as the production of biliverdin, a molecule that has also been
shown to have cytoprotective effects (110). The reciprocal is also true; NO may
be one of the strongest inducers of HO-1 (111).

1.3.3.1.1 CO Donors
Carbon monoxide-releasing molecules (CORMs) were designed to
overcome a number of drawbacks related to CO delivery, particularly with
respect to controlled, measurable and safe delivery (112,113). Gas mixtures offer
a number of constraints, especially related to the rapid increase of blood COHb
levels, leading to toxicity and interference with oxygen transport.
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Transition metal carbonyls, traditionally used as industrial catalysts during
purification, offer a safer, stable chemical form for CO delivery (112). The first
synthesised molecule, CORM-1, required activation with light to achieve
dissociative loss of CO. This drawback was soon overcome through the use of
ruthenium-based carbonyl complexes, CORM-2 and CORM-3. CORM-2 still had
limited solubility in water; this would pose a problem for use in pharmaceuticals,
but not in animal model. Water solubility of CORM-3 was achieved by glycination;
the substance has been shown to be safe in regards to cell viability (114). The
effects of CO have been clearly demonstrated in experiments where
comparisons in responses were made to those with inactivated CORMs (those
that were intentionally depleted of CO through dissolution) (112). CORM-3 and
CORM-A1 have been paramount in developing hypotheses related to the doserelated effects of CO. CORM-3 has a very short half-life (less than one minute),
while CORM-A1 releases CO at a much slower rate (half-time of 21 minutes).
The vasorelaxation due to CORM-3 is quite rapid and profound and likely works
through different mechanisms than the more prolonged but milder effects of
CORM-A1 (115).
CO delivery of CORM-3 mimics the effects of endogenously derived CO,
and has since been shown as an effective protective agent in a variety of animal
models of disease, ranging from sepsis, acute limb CS, transplantation, cardiac
disease and I/R injury (113,115). For example, in a rat model of cardiac I/R
injury, CORM-3 attenuated cell death during hypoxia and re-oxygenation, clearly
reducing the infarct size – an effect completely inhibited by a KATP channel
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blocker (116). In another study, cardiac allograft time to rejection was increased
from 9 days to over 25 days post-transplant in rats treated with CORM-3 (116). In
a rat model of surgical ileus of the small bowel, CORM-3 reduced the
development of paralytic ileus, and limited leukocyte infiltration. Finally, In a
caecal ligation and puncture (CLP) animal model of sepsis, CORM-2 was able to
inhibit upstream molecules implicated in severe sepsis, preventing downstream
sequelae while improving animal survival (117).

1.3.3.2 Hydrogen Sulphide
Hydrogen sulphide (H2S) has only recently been recognized as an
important endogenous mediator of cellular activity, along with NO and CO (87).
H2S is a colourless gas with a distinct foul odour of rotten eggs, attributed to the
bacterial breakdown of organic matter without oxygen. Similar to CO, in
appropriately high doses, H2S is quite poisonous, particularly to the nervous
system, by forming a complex with iron and cytochrome enzymes, limiting
cellular respiration (118). While the biological role of H2S continues to be
elucidated, it has been implicated as an endogenous regulatory agent in
inflammation, oxidative stress and a control of vascular tone (87,119,120).
The role of H2S has largely been elucidated through inhibition of H2S
synthesis. Cellular production of H2S is cysteine-based and relies on two
enzymes, cystathionine γ-lyase (CSE) and cystathionine β-synthetase (CBS)
(Figure 1.2) (87). Both CBS and CSE are expressed in many tissues, including
the liver, kidney and brain (121,122). Recently, it has been hypothesized that
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Figure 1.2. Endogenous formation of hydrogen sulphide.
Reproduced from Szabó (2007), with permission.
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CSE depletion may contribute to the development of Hungtinton’s disease,
suggesting a potential role of H2S in the neurodegeneration and loss of cellular
protection; cysteine supplementation appears to reverse the cellular changes
(123). Beyond human cells, bacteria, including those of the intestinal flora,
produce H2S. Enteric H2S absorption is limited by the epithelial enzymes within
the intestine; these metabolize sulphide to thiosulphate and sulphate. As as
result, local increases in concentrations are prevented, and systemic absorption
of this gas is limited (124,125). Detoxification appears to be highly localized to
the caecum and right colon, leading to the postulation of the role of H2S in some
forms of colitis (124).
Outside of the brain, CSE inhibitors have been used to block the
production of H2S in the aorta, portal vein and ileum. Exogenously applied H 2S
has been demonstrated to produce vasorelaxation, and, at least in part, appears
to work in synergy with NO (particularly in the aorta, where H2S may potentiate
the effects of NO) (126). The vasorelaxation may also be mediated through the
endothelial calcium-dependent potassium channels and ATP-sensitive potassium
channels (127,128). Similar to NO and CO, the vascular relaxation most likely
involves cGMP pathways, either through increased synthesis, reduced
degradation or combination of both, although cGMP-independent pathways also
exist (129). The effect of H2S depends on its administered dose. Rapidlyreleasing molecules are more likely to have an effect through cGMP compared to
slow-releasing donors. The exact mechanism of cGMP increase is likely
mediated through phosphodiesterase (PDE) inhibition (130–132).

37

1.3.3.2.1 H2S Donors
The original H2S-releasing compounds were hydrogen salts, most
commonly in the form of sodium sulphide (NaHS). Aqueous salts completely
dissolve in solution, and, in this case, release all of the cations and anions (i.e.
hydrogen sulphide) instantaneously. This is not what happens in the biological
systems, and is responsible for much of the confusion regarding the actions of
H2S when tested in vitro and in vivo. In order to better mimic biological rates of
release and tissue concentrations, other H2S-releasing organic molecules were
pursued. This led to the development of morpholin-4-ium 4-methoxyphenyl
(morpholino) phosphinodithioate, also commonly known as GYY4137 (133).
GYY41317 has traditionally been used in the industry for the vulcanization
of rubber, and was “re-discovered” as a potentially improved agent for H2S
delivery. One of the first descriptions of the use of GYY4137 in a biological
system compared it against NaHS (133). Using anesthetised rats, GYY4137
demonstrated a much different profile of H2S release from that of NaHS: a
sustained increased in plasma concentration of H2S is seen with GYY4137,
versus the near instantaneous peak of H2S with NaHS (133). NaHS-induced
apoptosis has been of concern; the slow release of H2S from GYY4137 resulted
in no apoptotic effect, as well as no effect on p53 (which was the reported
mechanism of cell death from NaHS) (134). The difference in effects on
cardiovascular function between the two compounds was also notable: NaHS
had significant negative ionotropic and chronotropic effects on rat heart, while
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GYY4137 had displayed none. The transient vasodilation and blood pressure
reduction was slower in onset, and longer lasting with GYY4137, and appears to
be mediated by the opening of vascular KATP channels. In the rat model of
lipopolysaccharide-induced endotoxic shock, GYY4137 was shown to relax
vasculature and normalize blood pressure (135). While the mechanism of action
of GYY4137 is unclear, it has been hypothesized to be related to modulation of
NF-κB, resulting in a release of nitric oxide and vasodilation (136). Additionally,
GYY4137 demonstrated hepatic and renal protection, as measured by alanine
transaminase (ALT) and creatinine, respectively. The anti-inflammatory effects of
GYY4137 has been demonstrated by the reduction in lung MPO and proinflammatory cytokines, coupled with an increase in anti-inflammatory cytokine,
IL-10 (135). One of the most interesting findings from this work was the
importance of timing: administration of GYY4137 one hour prior to the induction
of shock had little, or no anti-inflammatory effect (135).

1.4 THE PURPOSE OF THE THESIS
The goal of this work was two-fold. The first objective was to characterize
the incidence of IAH in a mixed medical-surgical ICU population using modern
definitions of IAH and modern measurement techniques, according to consensus
guidelines (24). While a single contemporary study (35) has attempted a similar
goal, it is our hope that the results generated will be more generalizable. We
hypothesize that IAH will be more prevalent when screening consecutive patients
compared to only measuring IAP in those deemed high risk. Finally, our results
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were hypothesis-generating, with respect to factors which influence the
development of IAH, as well as the impact of IAH on patient mortality.
The second goal of this thesis was to investigate a possible therapeutic
effect of CO and H2S on the physiological sequelae of ACS, using an animal
model (rat). The mainstay of treatment of ACS is prompt recognition and early
decompressive laparotomy; however, even with maximal therapy, mortality
remains high (80). Both CORM-3 (CO donor) and GYY4137 (H2S donor) have
demonstrated potent protective effects in ischemia-reperfusion injury in other
non-abdominal compartment syndromes (84,85,112), as well as various models
of systemic inflammation and shock (87,98).
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CHAPTER 2:

INCIDENCE OF INTRA-ABDOMINAL HYPERTENSION IN
A MIXED MEDICAL-SURGICAL INTENSIVE CARE UNIT

2.1 INTRODUCTION
Intra-abdominal hypertension (IAH) and abdominal compartment syndrome
(ACS) are increasingly recognized in critically ill patients and have been shown to
contribute significantly to both morbidity and mortality (1–3). Equipoise remains
regarding the clinical importance of IAH. For instance, IAH has been shown to be
an independent predictor of mortality in a number of studies (1,4–6), while having
no association in others (7–9). Further, published risk factors for IAH are based on
isolated patient cohort data; the studies are mostly retrospective and use
inconsistent definitions and measurement techniques for intra-abdominal pressure
(IAP). The established risk factors are broad, and apply to the majority of critically
ill (10,11). Indeed, based on the seminal papers on the epidemiology of IAH (1,2),
consensus guidelines by the World Society of the Abdominal Compartment
Syndrome (WSACS) have advocated for standardized measurement of IAP,
standardized definitions and reporting (11).
There is a lack of high quality studies evaluating IAH in ICU patients, making
determination of the true incidence difficult. These concerns have been highlighted
in a recent review (12), and at least one recent study has attempted to generate
higher quality data (9). The majority of incidence studies measure IAP in patients
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thought to be at high risk, despite no definitive indications regarding the subset of
patients at highest risk of developing IAH (13).
This study aimed to apply the WSACS definitions to consecutively admitted
patients in a mixed medical-surgical ICU to determine the incidence of IAH.
Secondarily, risk factors for IAH and ICU mortality were investigated in a
descriptive model.

2.1.1 Outcomes
The primary outcome was the incidence (period-prevalence) of IAH in a
mixed medical-surgical intensive care unit population, defined by the event rate of
IAH during patients’ ICU stay. The WSACS recognizes the limitations of a single
IAP pressure measurement, and formally define IAH as “sustained or repeated
pathological elevation in IAP ≥12mmHg.” In the consensus guidelines, maximal
IAP measurement was suggested, although consideration is given to using mean
or median values of consecutive measurements (11). Given this, two consecutive
measurements of IAP ≥12 mmHg during admission represented an event of IAH,
and were used to calculate incidence, as well as to perform the analysis. This
definition is consistent with the most recent IAH epidemiology literature (4,9).
Secondary outcomes included the point prevalence of IAH on admission
(defined by the mean of the first two IAP measurements), the identification of IAH
risk factors (at the time of admission) and ICU mortality. The diagnosis of ACS was
made at the discretion of the treating physician and invariably involved the general
surgical team.

54

2.1.2 Hypothesis
We hypothesized that the incidence of IAH would be lower than that
reported in the literature.

2.2

METHODS
A prospective, observational cohort study at the Critical Care Trauma

Centre (CCTC), Victoria Hospital in London, Ontario was conducted. Victoria
Hospital is a tertiary care teaching hospital and level one trauma centre with a
catchment area of two million people. The CCTC is a 28-bed unit, with
approximately 50% surgical and 50% medical patients at any given time. We
adhered to the strengthening of reporting of observational studies in epidemiology
(STROBE) guidelines (14). Recruitment began September 9th, 2015 and
continued until Dec 31, 2015; ICU follow-up concluded on Jan 18th, 2016 for all
patients. Ethics approval was obtained from the Health Sciences Research Ethics
Board at the University of Western Ontario (HSREB#106031). Patient consent for
bladder pressure measurement and data collection was required. The trial was
registered at ClinicalTrials.gov (NCT02514135).

2.2.1 Sample Size
A sample size calculation was performed to determine the number of
patients required given an incidence of 25% (2) and an error of 5% and calculated
a sample size of 289 patients (Table 2.1).
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2.2.2 Eligibility Criteria
All adult (>18 years of age) patients admitted to the CCTC with a bladder
catheter in-situ were considered for inclusion. Exclusion criteria included death
prior to IAP measurement, lack of informed consent, pregnancy, discharge prior to
IAP measurement, no IAP measurement within 24 hours of admission, organ
donors, and cases where the care team declined to enroll the patient.

2.2.3 Bladder Pressure Measurement
Bladder pressure was measured using the modified Kron technique, the method
suggested by consensus guidelines (11). Briefly, residual urine from the bladder
was completely drained, and the bladder catheter clamped. Twenty-five millilitres
of sterile saline was injected into the bladder via a port on the Foley catheter. IAP
was measured via a pressure transducer at end-expiration and was expressed in
mmHg. To ensure the study was pragmatic and represented normal practise, the
ICU nurse assigned to each patient performed the measurement. All the nurses
had the opportunity to ask questions about IAP measurement prior to the study
commencement. The ICU nurses have previous clinical experience measuring IAP
but for study purposes detailed instructions were provided in person and via the
hospital website. An IAP measurement was performed at each 12-hour shift, and
recorded in the patient care record. Study personnel collected data on a daily basis
and were available to answer study related questions.
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Table 2.1.

Sample size calculation.

Confidence limits at % of 100

Prevalence

±2.5%

±5%

±10%

10%

553

139

35

15%

784

196

49

20%

983

246

62

25%

1152

289

73

30%

1290

323

81

35%

1397

350

88

40%

1473

369

93

45%

1519

381

96

50%

1535

384

97

N = p(1-p)(Z/E)2 = 0.25(1-0.25)(1.96/0.05)2 = 289
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2.2.4 Data and Statistical Analysis
Baseline characteristics (age, sex, body mass index (BMI), admitting
diagnosis, service, operative urgency, co-morbidities, Acute Physiology and
Chronic Health Evaluation (APACHE) II score and Multiple Organ Dysfunction
Scores (MODS)) were recorded. The incidence was calculated as the primary
outcome, using two consecutive IAP measurements of ≥12 mmHg as the event
rate. The results were used to divide the population into two groups: “IAH” or “no
IAH.” Data were expressed as percentages, mean and standard deviation (SD) or
median and 25-75% inter-quartile range (IQR) as appropriate. The Student t-test
was used to analyse normally-distributed continuous data, while non-parametric
testing was used for non-normally-distributed data. Pearson’s χ2 test was used to
determine the relationship between categorical variables. The trial type and design
were not powered for analyses of risk factors; however, an explanatory model was
developed as a secondary outcome, by performing multivariate logistic regression,
with IAH as the dependent variable and admission characteristics as independent
variables. An adjusted odds ratio for ICU mortality was calculated using
multivariate logistic regression, including age, sex (female as reference), IAH
(categorical), ventilation status (categorical) APACHE II score (continuous),
sepsis, obesity (BMI>30kg/m2), lactate (>2.4mmol/L) and high fluid balance (>3L
in 24 hr). All analysis was performed using SPSS v. 22 (IBM, Armonk, NY) and
STATA 14.1 (StataCorp, Texas, USA).
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2.3

RESULTS
Three hundred and eighty six patients were admitted to the intensive care

unit between September 9, 2015 and December 31, 2015. A total of 285 patients
were included in the final analysis (reasons for exclusion are outlined in Figure
2.1). The demographics and clinical characteristics are outlined in Table 2.2. The
prevalence of IAH on admission was 30%, and a further 15% developed IAH during
their ICU stay. The overall period prevalence was 45±6%.
The majority (55%) of patients were diagnosed with Grade I IAH. Increasing
grade was associated with increasing morality (Figure 2.2). Of the eight patients
who developed ACS, seven were medical admissions, while one was surgical.
Four patients underwent abdominal decompression, although only one patient
(12.5%) survived. Out of a possible of 2993 possible bladder pressure
measurements, 2250 (75%) were performed. The average IAP throughout
admission was 9.3±3.7mmHg. In patients who were diagnosed with IAH, the
average IAP was 12.±3.1mmHg. In the patients who did not have IAH, the average
IAP was 7.1±2.5mmHg. Predictors of IAH on multi variable logistic regression are
shown in Table 2.3.
Overall ICU mortality was found to be 20%, and was significantly higher in
patients diagnosed with IAH (Table 2.4). In a multivariable model attempting to
predict ICU mortality, IAH was an independent predictor of ICU mortality (OR 2.95,
95% CI 1.27-6.84, p=0.01, Table 2.5). IAH on admission (Mean of first two IAP ≥
12mmHg) was an independent predictor of mortality in the same model
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Consecutive admissions from
Sept 9, 2015 to Dec 31, 2015
(n = 386)
Reason for exclusion (n = 101)
No consent (n = 26)
No foley catheter (n = 23)
Death before IAP (n = 22)
No IAP (n = 14)
Team declined (n = 7)
Discharged before IAP (n = 4)
Organ donor (n = 3)
Pregnancy (n = 2)
Patients included in analysis
(n = 285)

IAP = Intra-abdominal Pressure

Figure 2.1. Included patients and reasons for exclusion from analysis.
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Table 2.2.

Baseline characteristics and physiologic measures of patients
with and without IAH diagnosed during admission.

n, (%)
Age, y, mean (SD)
Male, n (%)
BMI, kg/m2, median (IQR)
Admission Type
Medical, n (%)
Surgical, n (%)
Trauma, n (%)
Post-Operative, n (%)
Elective, n (%)
Emergent, n (%)
Comorbidities
Diabetes, n (%)
Insulin, n (%)
CAD, n (%)
Steroid Use, n (%)
Metastatic Cancer, n (%)
Dialysis, n (%)
AIDS, n (%)
Cirrhosis, n (%)
COPD, n (%)
CHF, n (%)
Hypertension, n (%)
Hematologic Cancer, n (%)
Current Smoker, n (%)
Ex-Smoker, n (%)
Physiology
APACHE II, mean (SD)
MODS, mean (SD)
Mechanical Ventilation‡
Septic†, n (%)
Lactate, mmol/L, mean (SD)
Fluid Balance*, mL, median
(IQR)
Total pRBC, units, mean
(SD)

All

No IAH

IAH

p-value

285
60 (18)
182 (64%)
26 (8)

157 (55%)
57 (19)
98 (62%)
25 (7)

128 (45%)
63 (16)
84 (66%)
28 (9)

N/A
0.01
0.7
0.001

150 (52%)
91 (31%)
46 (16%)
93 (32%)
41 (44%)
52 (56%)

84 (54%)
52 (33%)
21 (14%)
52 (33%)
27 (52%)
25 (48%)

65 (51%)
39 (30%)
24 (19%)
41 (31%)
14 (34%)
27 (66%)

0.5

79 (28%)
33 (12%)
56 (20%)
11 (4%)
16 (6%)
13 (5%)
2 (1%)
12 (4%)
55 (19%)
28 (10%)
144 (50%)
15 (5%)
93 (33%)
73 (25%)

36 (23%)
16 (10%)
24 (15%)
5 (3%)
7 (4%0
5 (3%)
2 (1%)
6 (4%)
35 (22%)
16 (10%0
67 (43%)
7 (4%)
54 (35%)
43 (28%)

42 (33%)
17 (13%)
32 (25%)
6 (5%)
9 (7%)
8 (6%)
0
6 (5%)
20 (16%)
12 (9%)
76 (60%)
8 (6%)
38 (31%)
30 (24%)

0.08
0.4
0.04
0.6
0.4
0.3
0.2
0.7
0.2
0.8
0.006
0.5
0.4
0.5

28 (9)
6 (3)
227 (79%)
82 (29%)
2.4 (2.4)
1640 (2749)

26 (8)
5 (3)
114 (72%)
27 (17%)
2.3 (2.4)
1135 (2540)

31 (9)
7 (3)
113 (88%)
55 (43%)
2.6 (2.4)
2019 (3284)

<0.001
< 0.001
0.001
<0.001
0.27
< 0.001

1.4 (3.5)

0.7 (1.3)

2.4 (4.9)

< 0.001

0.9
0.09

IAH was defined as two consecutive measurements of IAP≥12mmHg; Body Mass Index, BMI;
Coronary Artery Disease, CAD; Acquired Immune Deficiency Syndrome, AIDS; Chronic
Obstructive Pulmonary Disease, COPD; Congestive Heart Failure, CHF; Acute Physiology and
Chronic Health Evaluation, APACHE; Multiple Organ Dysfunction Score, MODS; pRBC, packed
red blood cells;
†Defined according to international guidelines (11)
‡At least one ventilator day
*At 24 hours
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60%

50%

Patients (%)

40%
Medicine
30%

Surgery
Trauma

20%

Mortality

10%

0%
0

1

2
Grade of IAH

3

4

Figure 2.2. Incidence and mortality stratified by grade of IAH.

62
(OR 2.90, 95% CI 1.37-6.09, p=0.005). The most common cause of death for all
patients was withdrawal of life-sustaining therapy (73%), followed by cardiorespiratory death (23%) and brain death (2%).

2.4

DISCUSSION
The incidence of IAH in our missed medical-surgical ICU population was

45±6%. This finding is consistent with the most recent and largest prospective
study on mixed medical-surgical ICU admissions that demonstrated an incidence
of 39% (9). Furthermore, IAH was present in all admission types (medical, surgical,
trauma) and in those not traditionally screened, such as non-ventilated patients.
This also represents the first prospective study adhering to consensus guidelines
(11) to show an association between IAH and ICU mortality. Patients diagnosed
with IAH were close to three times more likely to die in the ICU, compared to those
without IAH, independent of illness severity and other traditional predictors.
Since the first 2006 WSACS IAH and ACS (15,16), (with an update in 2013
(11)), there have been at least four prospective observational studies on the
epidemiology of IAH in mixed ICU populations (Table 1.2) (4,9,17,18).
Unfortunately, all but one (9) have been under-powered, recruiting less than half
of the patients required to accurately report the incidence of IAH within an
appropriate margin of error (4,17,18). The Australian, prospective observational
cohort which represents the best study to-date regarding the incidence of IAH/ACS
using modern definitions (9). Regrettably, the generalizability of their work may be
limited, as the patient population appeared to be dominated by those undergoing
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Table 2.3.

Patient outcomes by presence or absence of IAH.

Outcomes

All

No IAH

IAH

p-value

Ventilation Days†, median (IQR)

6 (7)

3 (4)

9 (9)

< 0.001

Vasoactive Medication Days†,
median (IQR)

1 (4)

0 (2)

3 (5)

< 0.001

Death in ICU, n (%)

56 (20%)

18 (11%)

38 (30%)

< 0.001

Death in hospital‡, n (%)

64 (22%)

25 (16%)

39 (31%)

0.004

5 (6)

4 (4)

7 (12)

< 0.001

ICU length of stay, d, median (IQR)
†A

day is counted if patient had vasoactive drug or ventilation at any point of any duration
at 30-days

‡Censored
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Table 2.4.

Multivariable logistic regression for IAH.

Variable

Odds Ratio

95% CI

p-value

APACHE II

1.01

0.97-1.06

0.6

Sepsis

2.57

1.31-5.05

0.006

Obesity

2.94

1.52-5.70

0.001

Age

1.02

0.98-1.03

0.09

Male Gender

1.47

0.80-2.68

0.2

Mechanical Ventilation

2.51

1.09-5.81

0.03

Fluid Balance > 3L*

2.02

1.07-3.80

0.03

Lactate > 2.4mmol/L*

0.97

0.52-1.8

0.9

Obesity was defined as Body Mass Index >30 kg/m 2; Acute Physiology and Chronic Health
Evaluation, APACHE; Age and APACHE II are continuous variables; *At 24 hours
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Table 2.5.

Multivariable logistic regression for ICU mortality.

Variable

Odds Ratio

95% CI

p-value

IAH

2.95

1.27-6.84

0.01

APACHE II

1.10

1.04-1.16

0.001

Sepsis

0.86

0.37-2.02

0.7

Obesity

1.85

0.83-4.1

0.1

Age

0.99

0.97-1.02

0.5

Male Gender

1.37

0.62-3.04

0.4

Mechanical Ventilation

0.47

0.15-1.46

0.2

Fluid Balance >3L*

2.67

1.26-5.7

0.01

Lactate >2.4mmol/L*

0.64

0.28-1.45

0.3

IAH was defined as two consecutive measurements of IAP≥12mmHg; Obesity was defined
as Body Mass Index >30 kg/m 2; Acute Physiology and Chronic Health Evaluation,
APACHE; Age and APACHE II are continuous variables; *At 24 hours
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cardiothoracic surgery. The study did not contain trauma patients, and their overall
ICU mortality of 11% is very low, likely drive by a preponderance of elective cases.
Our results did find a similar incidence of IAH but a significantly higher overall
mortality.
In our study, IAH was equally distributed between medical, surgical and
trauma admissions, confirming the hypothesis that intra-abdominal pathology is
not required for the development of IAH and that a broad patient population is
affected (6,19,20). Patients diagnosed with IAH differed from non-IAH patients in
a number of ways, including: BMI, co-morbidities, APACHE II score, MODS, and
being mechanically ventilated. While the difference in age was found to be
statistically significant, it is not clinically meaningful. Variables which explained the
presence of IAH that were consistent with previous literature included: sepsis,
obesity, fluid balance greater than three liters at 24 hours and mechanical
ventilation (9–11). All but obesity are related to the underlying disease process,
and serve, at least in part, as surrogate measures of illness severity. In particular,
fluid balance was an important predictor, as patients with IAH received nearly one
litre more on admission than those without IAH. As one of the management
strategies of IAH is to avoid over-resuscitation, this finding supports the early
implementation of vasopressors, particularly in sepsis, to avoid IAH, and potentially
death (21).
IAH has been suggested to be an independent risk factor for mortality. While
no prospective, goal directed, randomized control trials have been performed,
centres that regularly monitor IAH and adhere to clinical guidelines appear to
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experience a reduced rate of ACS (13,22). One large prospective, observational
study demonstrated a reduced incidence of ACS, reduction in ventilator days and
survival to discharge (both raw and severity-adjusted) with the use of protocoled
bladder pressure monitoring and treatment according to consensus guidelines
(22). There continues to be conflicting reports on the use of IAH as a predictor of
mortality (1,4–9). We have demonstrated that even when controlling for other
known predictors of mortality, IAH is an independent predictor of mortality. This is
contradictory to Iyer et al (9), likely because of their patient population (largely
elective cardiac surgery patients), and the low incidence of higher grades of IAH.
When considering Grades II and above in their study, IAH was predictive of
mortality.
ACS was seen in eight patients (3%), of whom half underwent
decompressive laparotomy, yet only one patient survived. Predictors for the
development of ACS were not considered in the current study, due to the relatively
low number of outcomes: a challenge that plagues much of the literature on this
topic (10,11). Clearly not all patients with IAH progress to ACS and it is difficult to
predict which patients with IAH will progress to ACS. Clinically, the assumption is
that if the progression from IAH to ACS can be prevented with treatment, mortality
will be reduced (23).
The major strengths of our study are its prospective natures and its mixed
medical-surgical, high acuity participants. Furthermore, the study design was
pragmatic, where individual nurses were measuring IAP, rather than study
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personnel, thereby increasing real-world applicability. Finally, the study was
appropriately powered to determine IAH accurately.
The study was not without limitations. One of these was that only 75% of all
IAP were completed. While this may reflect real world practice, it may limit
interpretation of the incidence. The reasons for such compliance rates are variable,
and related both to systems and personnel issues. Fortunately, less than 5% of
patients were excluded due to lack of an IAP measurement on admission. In
addition, the study was also single-centered, with IAP measurements only
performed every 12 hours.
Our study continues to expand the body of literature that identifies IAH as a
common entity in all critically ill patients. Our reporting adheres to the WSACS
guidelines and definitions, and provides a well-documented approach to the
epidemiology of IAH in a large, diverse patient population using pragmatic
methods. There is a clear association between IAH and ICU mortality in our patient
population. Future work should evaluate the effect of intervention on clinical
outcomes.
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CHAPTER 3:

CARBON MONOXIDE AND HYDROGEN SULPHIDE AS
POSSIBLE

THERAPEUTICS

FOR

ABDOMINAL

COMPARTMENT SYNDROME

3.1 INTRODUCTION
Critically ill patients are at risk of intra-abdominal hypertension (IAH),
resulting in metabolic, vascular and organ derangements, both at local and
systemic levels (1). In a subset of patients, abdominal compartment syndrome
(ACS) may result. ACS is defined by abdominal pressures greater than 20mmHg
and new onset end-organ failure. While ACS was originally described in postoperative abdominal aortic aneurysm patients (2), the syndrome is not limited to
surgical patients. Recent data would suggest that the incidence of ACS in critically
ill patients with and without intra-abdominal pathology is in the range of 1-5%.
Although various medical efforts may be employed, the mainstay of treatment for
ACS remains decompressive laparotomy (3–5), with on-going organ failure.
ACS results in decreased cardiac output, hypoperfusion of hepatic
microvasculature, cessation of the renal filtration gradient, and increased mucosal
permeability with bacterial translocation from the bowel (5). The resulting injury is
related to both, the ischemia caused by high abdominal pressures (to which the
gut is very sensitive), and the reperfusion injury following pressure relief (6–8).
Several animal models have attempted to simulate the ischemia-reperfusion (I/R)
of ACS by various methods, although pneumoperitoneum appears to be the most
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common (9–16). Previous work in our laboratory had demonstrated significant
hepatic microvascular changes, in addition to evidence of multi-organ dysfunction
and metabolic derangement, in a rat model of ACS (17).
Non-surgical treatments of ACS currently do not exist in a clinical setting.
Ideally, the incidence of IAH should be minimized by adhering to consensus
guidelines (1), but, as established in Chapter 2, it remains high. Decompressive
laparotomy is the only available method to effectively relieve the pressure and
restore end-organ perfusion; however, mortality remains high at ~80% (1,18).
While the mortality associated with ACS is multifactorial, it likely includes an
element of I/R injury. Previously, a number of compounds have been tested,
including minocycline, octreotide, dopamine, and glutamine (19–22). Recently,
carbon monoxide (CO) and hydrogen sulphide (H2S) have demonstrated promise
in reducing cellular injury and microvascular perfusion derangements in rat models
of acute limb compartment syndrome (23,24). CO and H2S are both produced
endogenously, protecting against I/R injury via anti-oxidant and anti-inflammatory
mechanisms that continue to be elucidated (25,26). CO- and H2S-releasing
molecules (CORM-3 (27–29) and GYY4137 (30,31), respectively) can be used to
deliver both compounds systemically and have been shown effective in rat models
of acute limb compartment syndrome (23,24).
The purpose of this study was to determine the effect, of CO and H 2S on
hepatic microvasculature, hepatic cell death, and inflammatory, metabolic and
renal dysfunction in a rat model of ACS. The ultimate goal is the development of
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non-surgical (pharmacological) therapy for ACS. We hypothesized CO and H2S
would reduce the systemic and organ injury as a result of ACS.

3.2

MATERIALS AND METHODS
The experimental protocol was approved by the Animal Use Subcommittee

of Canadian Council on Animal Care at the University of Western Ontario
(Appendix III). Animals were housed in clear plastic cages in pairs, at 12:12
light:dark cycle, and had free access to food and water. The sample size was
calculated with leukocyte rolling as the primary outcome based on the expected
results from Chadi et al. (17).

3.2.1 Animal Preparation
Male Wistar rats were anaesthetised by inhalational isoflurane (5%
induction 2% maintenance) in a 1:1 oxygen/nitrogen mixture. The left carotid artery
was cannulated to allow for systemic monitoring, fluid administration and
continuous blood pressure monitoring. The body temperature of the animal was
monitored via a rectal probe, and maintained constant at 37°C by the means of a
heat lamp. A 16-gauge and 14-gauge angiocatheters were inserted into the
peritoneum; these were used to generate pneumoperitoneum and to continuously
monitor the intra-abdominal pressure, respectively (Figure 3.1). At the conclusion
of the experiment, all animals were euthanized by an overdose of anaesthetic
agent.
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Figure 3.1. Schematics of the experimental setup for rat abdominal
compartment syndrome.
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3.2.2 CORM-3 and GYY4137
A

water

ruthenium(II),

soluble

CO

donor,

[Ru(CO)3Cl-glycinate];

CORM-3
molecular

(tricarbonylchloro-glycinateweight

295

gmol-1)

was

synthesized by us, according to an established protocol (26). Fresh CORM-3 was
prepared by dissolving it in isotonic saline just prior to injection. The inactive form
(iCORM-3) was prepared by dissolving CORM-3 in saline 72 hours prior to
injection, to allow the release of all CO from solution.
A water soluble H2S donor, GYY4137 (Cayman Chemicals, Ann Arbor,
Michigan, USA), was dissolved in a normal saline solution, just prior to the
administration (30,31).

3.2.3 Elevation of IAP as a Model of ACS
A fitted Plaster of Paris cast was applied around the abdomen of each rat
to limit distension of abdominal cavity. Care was taken to ensure the diaphragm
and rib cage of each rat was not obstructed. The plaster cast was activated with
water and moulded to the animal’s contours. The intra-abdominal pressure (IAP)
was raised to 20-30mmHg by insufflation with CO2, while an electronic
compartmental pressure monitoring system was used to continuously monitor the
intra-abdominal pressure (Synthes, USA). The elevated IAP was maintained for 2
hours. Sham animals were subjected to the same preparation, but the IAP was
kept at baseline of 0mmHg. Following the 2 hour period of ACS a midline
laparotomy was performed to decompress the abdomen and begin data collection
via IVVM and blood draws.
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3.2.4 Experimental Groups
Rats were randomly assigned to one of four groups: 1. sham (n=4), 2.
ACS+iCORM-3 (n=5), 3. ACS+CORM-3 (n=5), and 4. ACS+GYY4137 (n=5).
Randomization was based on day of the week. CORM-3 and GYY4137 were
administered at the dose of 10mg/kg and 50mg/kg, respectively, via the carotid
artery. Inactive CORM-3 served as the experimental control, to demonstrate the
physiological effects of ACS. Doses were chosen based on previous work on limb
compartment syndrome (23,24).

3.2.5 Intravital Video Microscopy (IVVM)
Abdominal organs were exposed through midline laparotomy. The animal
was then transferred to the stage of an inverted microscope (Nikon) and the liver
was exteriorized into a saline bath containing 5μg/mL fluorescent vital dye,
propidium iodide (PI, excitation 482nm; emission 616nm). PI stains all nuclei of
cells with severely compromised cell membranes. A plastic film was used to cover
the preparation and prevent the organ from drying. The temperature of the organ
bath was maintained by the means of a heat lamp at 32°C. Care was taken to
ensure that the time from laparotomy to first microscopy reading was minimized
(<5 minutes).
Hepatic sinusoidal perfusion and leukocytes within the post-sinusoidal
venules were recorded by translumination with 20x and 40x objectives,
respectively, in eight to twelve fields of view containing a complete hepatic vascular
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unit. Fluorescence microscopy was used to visualise the PI staining from the same
fields of view as those used to assess the sinusoidal perfusion. All videos were
captured into the computer for offline analysis. The entire IVVM recording lasted
20-30 minutes per animal.

3.2.6 Offline Video Analysis
Sinusoidal perfusion was assessed by counting the number of continuously
perfused (CPS), intermittently-perfused (IPS) and non-perfused (NPS) sinusoids
within a 36-point stereological grid, using standard stereological techniques and
was expressed at the % of total sinusoids. Sinusoidal diameters (D) were
measured using ImageJ (NIH, Bethesda, MD) software, by averaging 3 different
points along each sinusoid, and expressed in µm. Centreline velocity of red blood
cells (RBC) (V) was assessed within each sinusoid by using frame-by-frame
analysis and expressed as µm/s. Volumetric flow (VQ) in pL/s, and shear () (s-1)
were calculated using the formulas VQ = r2 x V and γ = 8V/D, respectively.
Hepatic injury was assessed by counting the number of PI-labelled cells within a
field of view and expressed per volume of tissue. Leukocyte activation was
assessed by counting the number of adherent and rolling leukocytes within postsinusoidal venules, and expressed per 10,000 μm 2. Venular area was measured
using ImageJ (NIH, Bethesda, MD). A leukocyte was considered adherent if it
remained stationary for at least 30 seconds, and rolling if the cell remained in
contact with the wall of the vessel during movement. The data analyst was blinded
to the intervention group.
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3.2.7 Blood Sample Analysis
At the conclusion of the experiment, arterial blood samples were taken from
each rat for the assessment of serum levels of alanine transaminase (ALT),
aspartate aminotransaminase (AST), alkaline phosphatase (AlkPhos), blood urea
nitrogen (BUN), creatinine, carboxyhemoglobin (COHb) and arterial blood gases
(pH, pCO2 and pO2), just prior to euthanasia.

3.2.8 Tissue Level of Myeloperoxidase (MPO) Activity
MPO was measured enzymatically, as published previously (17). Briefly,
MPO was extracted from lung, liver and small intestinal tissues by homogenization
in 0.1M phosphate buffered saline (PBS) at a 1:10 ratio, followed by centrifugation
at 6,000xg for 20min at 4ºC. The pellet was then reconstituted and sonicated in
acetic acid/CETOH buffer, and centrifuged at 6,000xg at 4ºC. The resulting
supernatant was then added to MPO cocktail (acetic acid and tetramethyl
benzidine (TMB)) and warmed to 37ºC. The enzymatic reaction was initiated by
the addition of hydrogen peroxide and stopped 3min later by catalase. Following
the addition of 0.2M glacial acetic acid, the samples were analysed
spectrophotometrically, at 655nm (Beckman DU-640). The MPO activity was
expressed as Units/ml tissue extract.

3.2.9 Statistical Analysis
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All statistical analyses were carried out using Prism 5.0 for Mac software
(GraphPad Inc.). All parameters were expressed as means ± standard error of the
mean (SEM), and analysed using one-way analysis of variance (ANOVA), with the
Tukey post-hoc test where appropriate to perform single-step multiple
comparisons. The significance level was set at p<0.05.

3.3

RESULTS

3.3.1 Systemic Leukocyte Count and COHb
Elevation of IAP led to a significant rise in systemic leukocyte count; CORM3 and GYY4137 treatment were able to decrease the severity of this response
(Figure 3.2). Application of CORM-3, GYY4137 or iCORM-3 had no effect on
COHb levels (Figure 3.2).

3.3.2 Hepatic Microvascular Perfusion
Elevation of IAP resulted in significant changes to hepatic sinusoidal
perfusion, as shown in Figure 3.3. The number of continuously-perfused sinusoids
decreased from 93±3% in sham to 69±9% in ACS+iCORM-3 (p<0.01), while the
number of non-perfused sinusoids increased from 2±1% in sham to 13±6% in
ACS+iCORM-3 (p<0.01). CORM-3 and GYY4137 treatments were able to restore
the number of continuously-perfused capillaries to 88±3% and 95±2%, respectively
(p<0.01), while iCORM-3 had no effect. Sinusoidal diameters, RBC velocity, VQ
and shear did not significantly differ in any group (Table 3.1).
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Figure 3.2. The effect of CORM-3 and GYY4137 on (A) total systemic
leukocyte

count

and

(B)

COHb

levels.

ACS-associated

inflammation was reversed by CO and H2S application, while having
no effect on COHb levels (one-way ANOVA p<0.05; *p<0.05 from
sham; †p<0.05 from ACS+iCORM-3).
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Figure 3.3. The effect of CORM-3 and GYY4137 on liver microvascular
perfusion following ACS. ACS-associated perfusion changes were
reversed by CO and H2S application (one-way ANOVA p<0.05;
*p<0.05

from

sham;

†p<0.05

from

ACS+iCORM-3).

CPS,

continuously perfused sinusoids; IPS, intermittently perfused
sinusoids; NPS, non-perfused sinusoids.
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Table 3.1.

The effect of CORM-3 and GYY4137 on hepatic sinusoidal
diameters, centreline RBC velocity, volumetric flow and shear
in rat model of ACS. There were no significant differences among
the groups.

2hr ACS
Parameter

Sham

iCORM-3

CORM-3

GYY4137

p-value

Sinusoidal
Diameter
(D) (μm)

8.6±0.9

8.5±0.8

8.0±0.5

7.2±0.4

0.49

Centreline
Velocity (V)
(μms-1)

203±10

187±20

240±22

279±57

0.27

Volumetric
Flow (VQ)
(pLs-1)

7.8±1.5

7.2±1.3

8.1±1.5

7.1±0.5

0.93

Shear (γ)
(s-1)

125.6±16.7

118.1±17.4

154.8±16.7

211.2±59.4

0.24

VQ = πr2 x V
γ = 8V/D
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3.3.3 Hepatocellular Death
Hepatocellular death, as measured by PI, significantly increased from 29±9
cells/0.1mm3 in sham to 489±188 cells/0.1mm3 (p<0.05) in ACS+iCORM-3 group.
CORM-3 and GYY4137 treatments were able to diminish tissue death to 88±44
cells/0.1mm3 and 127±50 cells/0.1mm3, respectively (p<0.05) (Figure 3.4).

3.3.4 Inflammation
Elevation of IAP led to significant leukocyte activation, as demonstrated by
the adhesive interactions with liver vascular endothelium. Leukocyte adherence in
the post-sinusoidal venules was increased from 0.5±0.2 in sham to 17.4±5.2
leukocytes/30s/10,000μm2 in ACS+iCORM-3 (p<0.01). Leukocyte rolling also
increased from 1.5±1.2 to 6.6±1.4 leukocytes/30s/10,000μm2. CORM-3 treatment
led to a significant, 17-fold decrease in leukocyte adherence and 6-fold decrease
in leukocyte rolling (0.4±0.2 adherent leukocytes/30s/10,000μm2 and 1.0±0.5
rolling leukocytes/30s/10,000μm2, respectively, p<0.01). GYY4137 treatment led
to a significant, 8-fold decrease in leukocyte adherence, while having no effect on
leukocyte rolling (2.4±0.4 adherent leukocytes/30s/10,000μm2, p<0.01, and
6.4±1.7 rolling leukocytes/30s/10,000μm2, not significant) (Figure 3.5).

3.3.5 Tissue MPO
Lung, liver and small intestine MPO activity increased from 25.7±3.9,
13.9±0.7 and 25.2±4.4U/ml, respectively in sham to 110.3±9.9, 20.7±1.3 and
46.1±10.1U/ml, respectively in ACS+iCORM-3 (p<0.05). CORM-3 treatment led
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Figure 3.4. The effect of CORM-3 and GYY4137 on hepatocellular death
following ACS. ACS-associated hepatocellular death was reversed
by CO and H2S application (one-way ANOVA p<0.05; *p<0.01 from
sham; †p<0.01 from ACS+iCORM-3).
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B

Figure 3.5. The effect of CORM-3 and GYY4137 on leukocyte activation
following ACS: (A) adherence, (B) rolling. ACS-associated inflammation was
reversed by CO and H2S application (one-way ANOVA p<0.05; *p<0.05 from
sham; †p<0.05 from ACS+iCORM-3).
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to a significant decrease in MPO (65.3±11.0U/ml in lung, 16.5±0.6U/ml in liver and
23.1±3.3U/ml in small intestine, p<0.05), while GYY4137 had no effect
(92.0±17.7U/ml, 16.4±2.3U/ml and 40.6±11.1U/ml in lung, liver and small intestine,
respectively, not significant) (Figure 3.6).

3.3.6 Organ Function and Blood Gases
Elevation of IAP resulted in a significant increase in ALT and a trend
towards an increase in AST, from 37.2±2.6 0U/L and 70.5±11.5U/L in sham to
237.3±150.0U/L (p<0.05) and 508.3±333.1 U/L in ACS+iCORM-3 (p<0.05), while
having no effect on levels of AlkPhos or bilirubin (Figure 3.7). BUN and creatinine
also increased, from 5.6±0.5mmol/L and 12.0±1.2μmol/L, respectively, in sham to
16.8±1.0mmol/L (p<0.05) and 16.5±2.5μmol/L in ACS+iCORM-3 (Figure 3.8).
CORM-3 and GYY4137 treatments significantly attenuated the liver and kidney
damage (Figures 3.7 and 3.8).
Elevated IAP led to alterations in arterial blood gases (particularly pCO2)
and blood pH compared to sham; arterial blood gases and blood pH were
significantly improved by CORM-3 and GYY4137 treatments (Figure 3.9).

3.4

DISCUSSION
Abdominal compartment syndrome poses a challenge in critically ill

patients; decompressive laparotomy remains as the mainstay of treatment. In our

88

B

Liver Myeloperoxidase (U/ml)

A

*

25
20
15
10
5
0

Sham

iCORM-3 CORM-3 GYY4137

2hr ACS

C

Figure 3.6. The effect of CORM-3 and GYY4137 on tissue MPO in (A) lung,
(B) liver and (C) small intestine following ACS. ACS-associated
increase in MPO was attenuated by CO, but not H2S application
(one-way ANOVA p<0.05; *p<0.05 from sham; †p<0.05 from
ACS+iCORM-3).
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Figure 3.7. The effect of CORM-3 and GYY4137 on liver function tests
following ACS: (A) ALT, (B) AST, (C) total bilirubin, (D) direct
bilirubin. (one-way ANOVA p<0.05; *p<0.05 from sham; †p<0.05
from ACS+iCORM-3).
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Figure 3.8. The effect of CORM-3 and GYY4137 on kidney function
following ACS: (A) blood urea nitrogen, (B) creatinine. (one-way
ANOVA p<0.05; *p<0.05 from sham; †p<0.05 from ACS+iCORM-3).
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Figure 3.9. The effect of CORM-3 and GYY4137 on arterial blood gases
parameters. ACS-associated acidosis was reversed by CO and H2S
application (one-way ANOVA p<0.05; *p<0.05 from sham; †p<0.05
from ACS+iCORM-3).
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study, we investigated the impact of two possible novel pharmacologic
therapeutics in a rat model of ACS.
Sustained elevation of IAP resulted in significant and negative physiologic
effects at the microvascular, organ and systemic levels. These were most likely
secondary to ischemia-reperfusion (I/R) injury. At the microcirculatory level, we
found that the elevated IAP led to a significant increase in the heterogeneity of
sinusoidal perfusion after decompression, with a shift from continuous perfusion
normal to sham towards intermittent and non-perfused sinusoids in ACS group.
This effect was partially lessened by both CO and H2S donors CORM-3 and
GYY4137, respectively (Figure 3.3). While we found a decrease in the continuous
perfusion, the volumetric flow and sinusoidal diameters remained unchanged
(Table 3.1). The change in sinusoid perfusion has been classically described in
models of liver transplantation (32), where the effect appears to be secondary to
hypoperfusion and reperfusion (33). Hypoperfusion represents a state of ischemia
caused by the diminished blood flow, where liver sinusoidal endothelial cells
become damaged due to a lack of energy substrate and hypoxia (33). Ischemia is
known to result in an increased vascular permeability, leading to the formation of
local edema (34), which then further contributes to non-perfused segments of
microcirculation. In our rat model of ACS, the blood flow was not completely
occluded by the elevation of IAP, but rather the liver perfusion was subjected to
the state of low flow, until normal blood flow was restored on laparotomy. The
subsequent reperfusion injury then accentuated the microvascular dysfunction
(33) triggered during the period of IAP elevation by an inflammatory response and
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neutrophil accumulation (35), in response to hepatocellular death and the
subsequent release of pro-inflammatory cytokines/chemokines (36).
The protective mechanism through which both CORM-3 and GYY41317
work is likely multifactorial. While both molecules possess vasodilatory properties
(37,38), no changes in sinusoidal diameters were observed in our study (Table
3.1). However, vasodilation of larger, more proximal vessels cannot be ruled out.
It has been postulated that there are synergistic pathways through which the
gasotransmitters exhibit their effects. The anti-inflammatory and anti-oxidant
properties of both CORM-3 and GYY4137 have been well described (27,39,40).
One of the possibilities is that the scavenging of reactive oxygen species and the
reduction

of

neutrophil

activation

had

a

significant

impact

on

liver

microvasculature. Additionally, attenuation of liver sinusoidal perfusion failure may
have also been mediated through a nitric oxide pathway, which both CO and H 2S
are known to influence (41).
Hepatic cells undergo cell death in response to ischemia, but more so upon
reperfusion (42). The mechanism for hepatocellular death remains controversial,
but may be due to apoptosis, necrosis or a pathway common to both, termed
necroptosis (43). In our study, hepatocellular death in both the CORM-3 and
GYY4137 groups was significantly less than that in the iCORM-3 group, but greater
than in sham (Figure 3.4). Given the timing of our pharmacologic therapy
administration (i.e. just before decompression), the data suggests that the
reperfusion injury is responsible for the majority of cell death, reduced by both
CORM-3 and GYY4137. Again, the effect is likely multi-factorial, due to attenuation
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of inflammation, but also through direct suppression of apoptotic and necrotic cell
pathways (31,44–46).
Leukocytosis was demonstrated in post-sinusoidal venules (rolling and
adhesion to the endothelium), as well as through measurement of MPO in liver,
small intestine and lung after ACS (Figure 3.5 and Figure 3.6, respectively). Our
results are consistent with those of previous animal models of ACS demonstrating
an inflammatory response, which then led to multi-organ failure (47). While we did
not directly measure pro-inflammatory cytokines in this particular study, it has been
well established that I/R results in upregulation of TNF-α, interleukins and various
chemokines, which, in turn, leads to downstream activation of leukocytes (47). In
our study, we found a differential effect of CORM-3 and GYY4137 on leukocyte
rolling. CORM-3, but not GYY4137, reduced leukocyte rolling in postsinusoidal
venules. Leukocyte rolling and adhesion are mediated by differential expression of
various adhesion molecules (selectins, Ig superfamily, respectively), both of which
pre-empt transmigration (48). The evidence for CO (and CORM-3) on leukocyte
rolling and adhesion is more straightforward than that found for H2S: there are
consistent findings of anti-inflammatory effects, including down-regulation of
selectins and integrins (49–51). The actions of H2S are less straightforward.
Experimental evidence has identified H2S as a pro-inflammatory or antiinflammatory, depending on the administered dose, rate of release and donor
molecule (38,52–54). Our data certainly suggests that GYY4137 has antiinflammatory effects, and is consistent with other reports on this donor molecule
(31,38,54). Given that we did not investigate the molecular mechanics of
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inflammation in our in vivo studies, it is challenging to draw firm conclusions on the
differential effect of CO and H2S on leukocyte rolling; however the effect of both
substances on leukocyte adhesion is clear.
Further evidence that H2S and CO in fact acted as anti-inflammatory agents
in our experiment was seen with regards to their effect on tissue MPO levels. MPO
reflects accumulation of tissue polymorphonuclear cells (PMN), as MPO in
neutrophils is constant (55). In our study, we found that ACS resulted in significant
increases of MPO, particularly in lung, liver and small intestine. MPO has been
shown to be elevated in response to ischemia, but even more so in reperfusion
(56). In addition, elevation of MPO has been suggested as a marker of organ
damage rather than that of PMN aggregation (57). Previously, CORM-3 has been
shown to not only reduce MPO release, but also ameliorate the catalytic activity of
MPO on endothelial cells (58). While the degree of MPO reduction is less for
GYY4137 compared to CORM-3, this may be due to differences in local cellular
levels. In animal models using H2S donor NaHS, MPO levels were found to actually
increase (59,60), providing further evidence for the biphasic action of H2S (54).
Without measuring tissue levels of H2S or demonstrating a dose response, it is
challenging to draw conclusions regarding the reduced anti-inflammatory effect of
H2S compared to CO, other than to conclude that at the doses given, CORM-3 had
a greater effect overall.
The ACS-associated rise in serum markers of tissue injury and organ
function was significantly reduced in GYY4137 and CORM-3 groups, as evident
by levels of liver and renal enzymes (Figure 3.7 and Figure 3.8, respectively). Their
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effect of hepatic hypoperfusion may be significantly less, compared to the
reperfusion injury, similar to what we had observed with MPO levels (19). The
acute renal failure associated with ACS is usually related to renal vein constriction
(61); in our study, the effect was attenuated by the administration of CORM-3 and
GYY4137 (28,31,62,63). This would suggest that the mechanism of protection may
be related to the anti-oxidant properties of these molecules, contributing to the
reduction in reactive oxygen species. Multiple authors have demonstrated
previously, in cardiac ischemia-reperfusion injury, that CORM-3 was able to reduce
tissue oxidative stress (29,64). Similar results have been found for GYY4137 in
cardiac I/R models (65) and endotoxic shock (31), where similar protective effects
on serum biomarkers, as well as liver and renal function were observed.
Our study was not without limitations. First, we used only one dose of
GYY4137 and CORM-3, and therefore did not generate a dose-response
relationship, although we surmised, based on earlier experiments, that one may
exist (28,31). Another limitation is that our model of ACS represented a single
insult, although in the clinical settings the IAP can fluctuate. Finally, GYY4137 and
CORM-3 were given after a period of elevated IAP, and while significant protective
effects were demonstrated, the role of administration prior to the development of
ACS is unclear. It is possible that identification of patients at risk of IAH/ACS, and
pre-emptively medicating them may be a better alternative than treating them after
the syndrome had already developed.
Development and testing of therapeutics to reduce tissue injury in the
setting of abdominal compartment syndrome is important, particularly with
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increased use of early decompressive laparotomy for ACS (66,67). The high
mortality associated with ACS is likely multifactorial, and related not only to the
underlying pathology causing elevated abdominal pressures, systemic organ
failure and tissue ischemia, but also the reperfusion injury following decompression
(68). Our results suggest both CORM-3 and GYY4137 are promising
pharmacologic avenues for further investigation, capable of reduction of the
ischemia-reperfusion injury in ACS. Future work should evaluate the use of these
substances in the setting of on-going IAH, which is more common clinically.

3.5
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CHAPTER 4:

GENERAL DISCUSSION

4.1 OVERVIEW OF RESULTS
Intra-abdominal hypertension is common; 45% of 285 patients had at least
one episode of IAH during admission to the intensive care unit. The type of patient,
medical, surgical or trauma did not impact rates of IAH. Further, in our mixed
medical-surgical patient population IAH was an independent predictor or mortality;
patients with IAH were nearly three times more likely to die in the ICU compared
to patients without IAH. While our patient population was different compared to
recent reports on IAH, our reported incidence was very similar (Table 2.2). While
our study found a relationship between IAH and mortality this has been
inconsistent through the literature. The utility of treating IAH aggressively, to
potentially reduce mortality, has not been examined. Our final conclusions cannot
infer whether IAH is a marker of illness severity or an entity which, when treated,
will improve patient outcomes. Indeed, while many non-operative management
and preventative strategies have been described, the evidence for effectiveness
at reducing IAP and the impact on patient outcomes is limited.
Our study was not designed to examine factors that would predict
progression to ACS and had only eight patients (3%) that developed ACS, seven
of whom died in the intensive care unit. Drawing conclusions regarding risk factors
for ACS, or whether progression to ACS during admission might be preventable is
challenging given the small event rate. Further, the nature of a patient’s underlying
disease process can cloud interpretation of determining management by
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laparotomy, as this is against some goals of patient care. Several researchers do
suggest that given the improved techniques to manage the open abdomen,
decompressive

laparotomy

should

be

considered

earlier

than

current

recommendations (1). Non-operative strategies for the management of ACS do
not currently exist, nor are there options for preventing the reperfusion injury
associated with ACS.
The second objective of this thesis was to investigate two potential
therapeutics for ACS, CORM-3 and GYY4137. In our rat model of ACS both
CORM-3 and GYY4137 reduced the physiologic consequences of ACS. These
results corroborate similar animal studies of acute limb compartment syndrome,
and add to the evidence surrounding the potential for pharmacologic strategies to
be used in areas where surgery has traditionally been mandated. In addition, our
results postulate that there may be a role for CORM-3 and/or GYY4137 use in
conjunction with surgical treatment, in order to reduce the ischemia-reperfusion
injury associated with decompression.

4.2 FUTURE DIRECTIONS
A number of hypotheses were generated from the present work. It remains
unknown whether the IR injury of ACS and compartment syndrome in general is
clinically relevant at lower IAPs. The fluctuation of IAP over time may be
introducing cyclical IR injury. It remains unclear which patients have clinically
relevant IAH. Identifying patients in whom IAH is clearly affecting physiology or
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who will progress to ACS will be paramount in further study of potential nonoperative therapeutics for IAH. More rigorous trials are needed to determine if the
measurement and treatment of IAH lead to improved outcomes, such as survival.
This should be done in a randomized fashion where new patients to the ICU are
randomized to receive IAP monitoring and treatment, or not.
Pharmaceuticals for the treatment of elevated IAP and compartment
syndrome are still in early phases of development. The next steps include
extension to larger animals, such as pigs, and testing in IAH rather than ACS. The
potential population who would benefit is much larger for IAH than ACS. Finally, a
combination treatment with both CORM-3 and GYY4137 has shown promise in
acute limb compartment syndrome (2).

4.3
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APPENDIX II.

PATHOPHYSIOLOGY OF IAH

II.1 THE EFFECTS OF ELEVATED IAP ON ORGANS AND SYSTEMS
II.1.1 Gastrointestinal Tract
The arterial and venous blood flow of the gastrointestinal tract is sensitive
to elevation of IAP, even with normal cardiac output. Mesenteric artery blood flow
and intestinal mucosal blood flow are reduced significantly at pressures of
20mmHg (1,2). Microperfusion of the gut results in significant bacterial
translocation after periods of high IAP (1). Evidence of intestinal damage in the
mucosa has been determined by the acidosis associated with elevations in IAP;
this was further correlated with sepsis, hypotension, renal derangements and
death (3). The effect of severe acidosis has been demonstrated in both humans
and animals.
The splanchnic ischemia and resulting necrosis of bowel may play a key
role in multi-organ dysfunction (4). An uncontrolled inflammatory response in
multi-organ dysfunction syndrome (MODS) has been identified as an important
pathogenic component (5).

II.1.2 Liver
Hepatic microcirculation is diminished during laparoscopy and is rapidly
restored following abdominal deflation (6). In a porcine model of IAH/ACS,
hepatic artery and portal venous blood flow were significantly diminished even at
pressures as low as 10mmHg (7). Liver function tests following laparoscopy have
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been found to be significantly elevated, compared to open operations, and
elevated IAP seems to be the cause. The elevations are likely not clinically
significant and return to baseline within 48 hours, but this suggests that even
transient increases in IAP can influence liver function (8,9). Animal models of
ACS have demonstrated significant elevation in liver enzymes, coupled with
changes in hepatic microvasculature following periods of high IAP (10).

II.1.3 Renal System
Kron et al (11) originally diagnosed ACS following open abdominal aortic
aneurysmal repair by oliguria in the setting of adequate resuscitation. The
progress to anuria, despite volume expansion, characterizes ACS clinically.
While anuria typically does not occur until IAP of 25-30mmHg, oliguria can occur
between 15-20mmHg (12,13). The renal system relies on adequate cardiac
output, coupled with proportional arterial flow and resistance; these are
negatively affected with increasing IAP. Hence, direct compression of the renal
veins and cortical arterioles will limit the normal perfusion. even with an adequate
cardiac output (14). It has been demonstrated, in a porcine model of ACS, that
elevation of renal vein pressure to 30mmHg resulted in a significant decrease in
renal arterial blood flow and glomerular filtration, and could only partially be
reversed with decompression. In addition, the decreased renal flow naturally
increased the circulating levels of anti-diuretic hormone and aldosterone, further
contributing to an increase in vascular resistance (15,16).
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Clinically, the effect on the renal system (as observed by urinary output) is
one of the most profound, both with respect to the oliguria/anuria during ACS,
and the almost immediate diuresis following abdominal decompression.

II.1.4 Respiratory System
The relationship between abdominal and thoracic pressures was an early
discovery (17). Clinically, IAH and ACS are typically characterized by difficulty to
ventilate, with high settings, hypoxia and hypercapnia (18–20). The mechanism
appears to be due to diaphragmatic elevation leading to a reduction in intrathoracic space and dynamic lung compliance (21,22).The resulting ventilationperfusion anomalies result in hypoxia. Increased thoracic pressure leads to an
increased pulmonary vascular resistance (19,20), resulting in pulmonary
hypertension (19,20). The effects of IAH/ACS on the respiratory system are
perhaps best demonstrated by the almost immediate recovery of respiratory
function and ease of ventilation following decompressive laparotomy (11,19).

II.1.5 Cardiac
As abdominal pressure rises, equal force is exerted on all abdominal
structures, as established by Pascal’s laws. Preload and eventual cardiac output
are determined by venous return, which can be impaired at IAP as low at
15mmHg (23). Venous return from both the inferior vena cava and portal system
is reduced. Increased thorax pressure and diaphragmatic elevation also impede
the superior vena cava and reduce ventricular compliance, shifting the Starling
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curve, particularly at high pressures (i.e. >30mmHg) (24). The decrease in
cardiac output is compounded by an increase in afterload secondary to IAH
(18,23,25–27). Thus, the overall impact on cardiac output is dependent on a
number of factors, including volume status, where hypovolemia and PEEP
exacerbate the reduction in cardiac output.

II.1.6 Neurological
Reduced cerebral perfusion secondary to elevated abdominal pressure
can lead to intra-cranial derangement independent of pulmonary and
cardiovascular function (28–30). Intracranial pressure (ICP), as related to IAP,
appears to be mediated via raised intra-thoracic pressure, as animals with a
median sternotomy do not demonstrate any elevation in ICP with increasing IAP.
In the non-critically ill setting, chronic IAH has been suggested to be a cause of
benign intra-cranial hypertension in the morbidly obese patients (31).
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APPENDIX III: ANIMAL PROTOCOL APPROVAL LETTER

11.01.14
*This is the original approval for this protocol*
*A full protocol submission will be required in 2018*
Dear Dr. Lawendy:
Your animal use protocol form entitled:
Direct and Remote Organ Injury Following Compartment Syndrome
Funding agency Orthopaedic Trauma Association – Direct and Remote Organ Injury Following Compartment
Syndrome – Grant #R4889A04 has been approved by the University Council on Animal Care.
This approval is valid from 11.01.13 to 03.31.18 with yearly renewal required.
The protocol number for this project is 2009-083.
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an
internal scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health
certificates will be required.
ANIMALS APPROVED FOR 4 YEARS
Species
Strain
Rat
Pig

Wistar
Yorkshire-Landrace

Other Detail
150-350 g
50-60 kg

Pain
Level
C
B

Animal # Total
for 4 years
680
30

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are
familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety,
radiation safety, general laboratory safety) comply with institutional safety standards and have received all
necessary approvals. Please consult directly with your institutional safety officers.

c.c. R Bihari, T Carter, K Bothwell, P Coakwell
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